Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter

YORK, Pa., Feb. 9, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced financial results for the quarter ended December 31, 2011 (Second Quarter of Fiscal Year 2012).

Recent Highlights:

  • Signed a clinical development agreement for a novel device for targeted organ delivery in November 2011; Unilife will receive $1.4 million in initial revenues, which will be recognized through the Fourth Quarter of  Fiscal 2012
  • Completed a common stock offering of 8,250,000 shares with net proceeds of $33.8 million to the Company (November, 2011)
    • The additional capital strengthens Unilife's negotiating position with pharmaceutical companies
    • Broadened base of U.S. healthcare investors with long-term investment strategies
  • Awarded a two year contract with Premier Purchasing Partners, the nation's largest healthcare alliance, for the supply of the Unitract® range of 1mL safety syringes (October 2011)
  • Open market purchases of the Company's common stock of approximately $1.0 million by Unilife Chief Executive Officer, Alan Shortall (January - February 2012)

"Unilife has made excellent progress across all areas of its business during the quarter ended December 31, 2011.  As we enter calendar year 2012, I believe that we have the broad operational capabilities and high-performance team in place to achieve a series of previously announced key business milestones," stated Mr. Shortall.  

"In this regard, I recently made the decision to further increase my position as Unilife's largest shareholder with the purchase of approximately $1.0 million of common stock in the open market. This decision further underlines my confidence in the strength of Unilife's current business position.  I plan to continue purchasing Unilife common stock in the open market moving forward, in line with our trading policies and SEC regulations.

"In November 2011, we completed a capital raise that bolstered our cash position in order to help support the negotiation of favorable agreements with pharmaceutical customers, the continued expansion of our portfolio of proprietary devices, and to further increase our operational capabilities. An additional benefit of the capital raise is that through the placement of shares with primarily blue chip, healthcare dedicated and long-only funds, we have an expanded investor base and created greater liquidity for the Company's common stock," concluded Mr. Shortall.

Financial Results for Three Months Ended December 31, 2011

Revenues for the three months ended December 31, 2011 were $0.9 million compared to $1.8 million for the same period in 2010.  The variation in revenue reflects the Company's strategic decision to discontinue its contract manufacturing operation in December 2010 and instead, focus on the commercialization, production and supply of its own propriety line of products. In addition, during the three months ended December 31, 2011, the Company recognized revenue of $0.2 million related to the clinical development and supply of a novel device for targeted organ delivery.  

The Company's net loss for the three months ended December 31, 2011 was $12.9 million, or $0.19 per diluted share, compared to a net loss of $10.4 million, or $0.19 per diluted share, for the same period in 2010.  The increase in the net loss was primarily attributable to an increase in research and development expenses related to the development of additional advanced drug delivery devices. These amounts were partially offset by a reduction of $1.3 million in selling, general and administrative expenses.  

Adjusted net loss for the three months ended December 31, 2011 was $9.6 million, or $0.14 per diluted share, compared to $7.6 million, or $0.14 per diluted share, for the same period in 2010. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense.

As of December 31, 2011, the Company's cash, cash equivalents and restricted cash were $41.7 million.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. U.S. Eastern Standard Time on February 9, 2012, to review the Company's financial results, market trends and future outlook.  The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast.  An archive of the presentation and webcast will be available for 30 days after the call.  To listen, please go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of advanced drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com   

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

Non-GAAP Financial Measures

U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure.  The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures.  Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results.  Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.  A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.

General: UNIS-G




Investor Contacts (US):

Analyst Enquiries

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Lynn Piper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500






(Tables Below)

UNILIFE CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except per share amounts)

(unaudited)





Assets

December  31, 2011


June 30, 2011

Current Assets:




Cash and cash equivalents

$                                39,305


$                                17,910

Restricted cash

2,400


2,400

Accounts receivable

362


13

Inventories

685


626

Prepaid expenses and other current assets

307


381

Total current assets

43,059


21,330

Property, plant and equipment, net

53,826


54,020

Goodwill

12,752


13,265

Intangible assets, net

37


42

Other assets

1,027


821

Total assets

$                              110,701


$                                89,478

Liabilities and Stockholders' Equity




Current Liabilities:




Accounts payable

$                                  2,225


$                                  2,405

Accrued expenses

2,411


2,696

Current portion of long-term debt

5,276


2,274

Deferred revenue

2,702


2,706

Total current liabilities

12,614


10,081

Long-term debt, less current portion

25,743


20,413

Deferred revenue

3,897


5,412

Total liabilities

42,254


35,906

Stockholders' Equity:




Preferred stock, $0.01 par value, 50,000,000 shares authorized as of December 31, 2011;
 none issued or outstanding as of December 31, 2011 and June 30, 2011

-


-

Common stock, $0.01 par value, 250,000,000 shares authorized as of December 31, 2011;
 73,044,651 and 63,924,403 shares issued, and 73,015,981 and 63,905,053 shares
 outstanding as of December 31, 2011 and June 30, 2011, respectively

730


639

Additional paid-in-capital

207,304


169,590

Accumulated deficit

(142,887)


(120,332)

Accumulated other comprehensive income

3,440


3,775

Treasury stock, at cost, 28,670 and 19,350 shares as of December 31, 2011 and June 30, 2011, respectively

(140)


(100)

Total stockholders' equity

68,447


53,572

Total liabilities and stockholders' equity

$                              110,701


$                                89,478







UNILIFE CORPORATION AND SUBSIDIARIES

Consolidated Statement of Operations

(in thousands, except per share amounts)

(unaudited)










Three Months Ended
December 31,


Six Months Ended
December 31,


2011


2010


2011


2010

Revenues:








Industrialization and development fees

$                     249


$                       -


$                  1,689


$                  1,350

Licensing fees

646


630


1,318


1,207

Product sales and other

17


1,132


35


2,748

Total revenues

912


1,762


3,042


5,305

Cost of product sales

16


824


90


1,999

Gross profit

896


938


2,952


3,306

Operating expenses:








Research and development

5,262


2,442


9,560


4,218

Selling, general and administrative

6,712


8,028


12,895


15,269

Depreciation and amortization

1,157


878


2,150


1,665

Total operating expenses

13,131


11,348


24,605


21,152

Operating loss

(12,235)


(10,410)


(21,653)


(17,846)

Interest expense

639


32


922


64

Interest income

(26)


(82)


(56)


(204)

Other expense (income), net

2


(2)


36


(102)

Net loss

$              (12,850)


$              (10,358)


$              (22,555)


$              (17,604)

Loss per share:








Basic and diluted loss per share

$                  (0.19)


$                  (0.19)


$                  (0.35)


$                  (0.32)











UNILIFE CORPORATION AND SUBSIDIARIES

Reconciliation of Non-GAAP Measure

(in thousands, except per share amounts)

(unaudited)










Three Months Ended
December 31,


Six Months Ended
December 31,


2011


2010


2011


2010

Net loss

$              (12,850)


$              (10,358)


$              (22,555)


$              (17,604)

Share-based compensation expense

1,485


1,836


3,385


4,386

Depreciation and amortization

1,157


878


2,150


1,665

Interest expense

639


32


922


64

Adjusted net loss

$                (9,569)


$                (7,612)


$              (16,098)


$              (11,489)

Adjusted net loss per share - diluted

$                  (0.14)


$                  (0.14)


$                  (0.25)


$                  (0.21)











SOURCE Unilife Corporation



RELATED LINKS
http://www.unilife.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.